Mark A. Emalfarb
President and Chief Executive Officer
Mark A. Emalfarb is the founder of Dyadic. He has been a member of Dyadic’s board of directors since October 2004, served as its Chairman from October 2004 until April 2007 and from June 2008 until January 2015 and has served as President and Chief Executive Officer from October 2004 until April 2007 and from June 2008 until the present.
Since founding Dyadic in 1979, Mr. Emalfarb has successfully led and managed the evolution of Dyadic from its origins as a pioneer and leader in providing ingredients used in the stone-washing of blue jeans to the discovery, development, manufacturing and commercialization of specialty enzymes used in various industrial applications and the development of an integrated technology platform based on Dyadic’s patented and proprietary C1 fungal microorganism.
Mr. Emalfarb is an inventor of over 25 U.S. and foreign biotechnology patents and patent applications resulting from discoveries related to the Company’s patented and proprietary C1 fungus, and has been the architect behind its formation of several strategic research and development, manufacturing and marketing relationships with U.S. and international partners.
Mr. Emalfarb earned his B.A. degree from the University of Iowa in 1977.
Thomas L. Dubinski, CPA
Vice President and Chief Financial Officer
Thomas L. Dubinski, CPA has been Dyadic’s Vice President and Chief Financial Officer since August 1, 2014 and received his Bachelor of Science in Accounting from the University of Illinois, Champaign-Urbana.
Prior to joining Dyadic, he held senior management positions at Fortune 500 businesses with global operations. From 2012 to 2014, Tom served as a management consultant at CFO Solutions. Tom previously served as Finance Officer for Walgreens Infusion Services where he was responsible for the finance function of a division with approximately $1 billion in revenue, and he has also held other senior positions within Walgreens corporate finance from 2007 to 2011. Prior to Walgreens, Tom was Director of Finance for Novartis Medical Nutrition from 2005 to 2006 and Chief Financial Officer of Metal Technology Solutions, a private manufacturer of precision metal components, from 2002 to 2004. Tom is also an 18 year veteran of Abbott Laboratories, where he had senior finance leadership roles in the areas of commercial operations, product development and manufacturing from 1984 to 2002.
Ronen Tchelet, Ph.D
Vice President of Research and Business Development
Ronen Tchelet joined Dyadic in May 2013 and has been Dyadic’s Vice President of Research and Business Development since January 2016. Dr. Tchelet received his Ph.D. in Molecular Microbiology and Biotechnology from Tel Aviv University in 1993 and did his postdoctoral as EERO fellow at the Institute of Environmental Science and Technology (EAWAG) in Switzerland.
In the late 2000’s, he joined the API Division of TEVA Pharmaceutical Industries LTD., where he served as a Chief Technology Officer of Biotechnology. Dr. Tchelet leaded and directed the Research and Development Biotechnology department of TEVA’s fermentation plant in Hungary. In his work he managed and organized Biotechnology and Biosimilar projects that combined multidisciplinary areas such as development, operation, and production of API and biologics. In addition, from 2000 – 2005, Dr. Tchelet was the QA manager of COPAXONE® the flag ship TEVA¹s innovative drug.
From 2007 through 2013, prior to joining Dyadic, Dr. Tchelet became the founder and the Managing Director of Codexis Laboratories Hungary kft. (CLH) and a Vice President of Codexis Inc. At CLH, he established a state-of-the-art laboratory for strain engineering and all aspects of fermentation work including process optimization and scaling up. It was during this time that Dr. Tchelet engaged with the C1 technology that was successfully developed for the Biofuel and the Bio-Industrial enzymes fields.
Matthew S. Jones
Chief Commercial Officer
Matthew S. Jones joined Dyadic in 2016 as Dyadic’s Chief Commercial Officer. In this role, Mr Jones is responsible for leading Dyadic’s strategic partnering, licensing and commercial activities.
A veteran of the life sciences industry with two decades of commercial leadership experience and deal making, Mr. Jones has led and transformed commercial growth and M&A strategies for a diverse range of science businesses both in Europe and the US. Prior to joining Dyadic he served as Chief Commercial Officer for Concept Life Sciences from its formation until 2016 – prior to that, Mr. Jones was Vice President Global Sales & Business Development at Lonza Biologics, where he implemented new income-generating streams alongside capturing enterprise and cross-divisional synergies in manufacturing, research and client/vendor relationships. From 2009-2012 Mr. Jones served as Executive Vice President of Business Development & Marketing at Ricerca BioSciences LLC where key responsibilities included strategic deal making, royalty and asset license optimisation and marketing effectiveness. From 2003-2009 Mr. Jones was Senior Vice President of Business Development at MDS Pharma Services Inc. where he led the BioPharmaceutical commercial growth platforms. Mr. Jones has also held senior level biologic and clinical leadership roles within the biopharmaceutical industry with Alkermes, Inc. and from 1998 with GlaxoSmithKline PLC.